

Organized by: Oncology Center of Biomedical Education and Research
Oncology Unit, 3rd Department of Medicine, Medical School of Athens

4th LUNG CANCER Network

«From the Bench to the Bedside»

January 15-16, 2016, Hilton Athens, Greece



Accreditation from:
Panhellenic Medical Association

Under the auspices of:



SCIENTIFIC PROGRAM

Invitation Letter

The recent, increasing amount of knowledge regarding lung cancer, especially in the field of basic science, holds promise for personalized treatment of these patients that would provide more effective and less toxic therapeutic approaches, improving the prognosis of the patients with thoracic malignancies. On the other hand, the immense bulk and the rapid recycling of the new information makes difficult its understanding, evaluation and interpretation by the clinicians. Therefore, the «translation» of our recently acquired knowledge from the lab bench to the bedside is neither smooth nor is it without obstructions, due to the existing «gaps» in our understanding and the often contradictory «signals» from clinical trials.

The success of our three previous meetings has prompted us to organize the **4th Lung Cancer Network «From the Bench to the Bedside»**. Our aim is to narrow the distance between the bench lab and the patient's bed, between the clinical trials outcome and the routine practice, by bringing together basic scientists, clinical researchers and lung cancer specialists. Our multidisciplinary, international faculty will present the latest clinical data and provide treating physicians with practical information regarding the clinical significance of the histological, molecular and genetic profile of the tumor and how the implementation of targeted agents in the therapeutic algorithm changes the clinical practice of lung cancer patients.

Finally, we anticipate that our meeting, with the presence of our distinguished faculty, would provide the opportunity and motivation for discussions regarding the emerging therapies and set the pavement for the future research and strategies towards the personalized treatment of lung cancer patients.

We cordially welcome you all in Athens in January 15th and 16th 2016 for a stimulating, innovative and educational meeting.

Learning Objectives

At the end of our educational meeting, the participant will be able to:

- Acquaint with the new staging and pathology classification systems in lung cancer
- Recognize the clinical significance of molecular genotyping of lung cancer patients
- Understand the molecular pathways that hold promise for therapeutic intervention in lung cancer patients
- Update of Immunotherapy strategies for lung cancer
- Discuss the optimal methodology of evaluation of response in the era of translational research
- Recognize the importance of a multidisciplinary approach to the care lung cancer patients

Topics

- New IASLC lung cancer staging system
- New WHO lung cancer pathology classification
- Neuroendocrine lung cancer update
- Thymic cancer update
- Tumor heterogeneity
- Prognostic and predictive tumor markers
- Molecular signaling of LC
- NSCLC driver oncogenes
- Immunotherapy
- Evaluation of response
- Masterprotocols in lung cancer.
- Agents related-toxicity management
- Newer generation TKIs inhibitors

Target Audience

The meeting is designed for medical, radiation and surgical oncologists, pathologists, chest physicians, scientists, residents-in-training, fellows and other health care professionals interested in the basic and clinical research as well as in the management of thoracic cancers.

CME Accreditation - Auspice

The content of the meeting will be submitted for CME accreditation and we will request the auspices of ESMO, IASLC and ETOP.

The Chairs of the Meeting



Professor Kostas Syrigos



Professor Alex Adjei



Professor Rolf Stahel

Scientific Program

FRIDAY **January 15th** 2016

08:30-09:00 Registrations

09:00-11:00 Updates from 16th WCLC-IASLC (I)
Chair: **Fulden Yumuk, Giannis Gkiozos**

09:00-09:30 Screening for lung cancer - update and the ways for implementation. **Nir Peled**

09:30-10:00 Thoracic surgery updates. **Ramón Rami-Porta**

10:00-10:30 Radiotherapy updates. **Françoise Mornex**

10:30-11:00 Medical oncology update. **Vali Papadimitrakopoulou**

11:00-11:30 Coffee break

11:30-13:30 Updates from 16th WCLC-IASLC (II)
Chair: **Kostas Zarogoulidis, Michalis Toubis**

11:30-12:00 Nursing updates. **Liz Darlison**

12:00-12:30 Global tobacco control updates. **Elif Dağlı**

12:30-13:00 Supportive care updates. **Richard Booton**

13:00-13:30 Thoracic malignancies beyond NSCLC. **Fulden Yumuk**

13:30-13:45 Break

13:45-14:30 Industry satellite symposium *Sponsored by*  **MSD**
Chair: **Kostas Syrigos, Paris Kosmidis**

Predictive and prognostic biomarkers for the immune checkpoints inhibitors. **Rolf Staher**

14:30-16:30 Lunch break

16:30-18:00 New WHO pathology classification of lung cancer
Chair: **Fred Hirsch, Christos Kittas**

16:30-16:50 Thymic cancer classification update. **Michael den Bakker**

16:50-17:10 Squamous and undifferentiated tumors classification update. **Keith Kerr**

17:10-17:30 Adenocarcinoma: classification and implications. **William Travis**

17:30-17:50 Neuroendocrine tumor update. **Elisabeth Brambilla**

17:50-18:00 Discussion

18:00-18:30 Coffee Break

18:30-20:00 Pathologist and clinician interaction

Chair: **William Travis, Efstratios Patsouris**

18:30-18:50 Cytology, small and liquid biopsies in lung cancer.

18:50-19:10 Molecular classification of lung cancer.

19:10-19:30 Tumor heterogeneity: impact on drug development.

19:30-19:50 Endpoints in clinical trials.

19:50-20:00 Discussion

**Keith Kerr
David Carbone**

**Charles Swanton
David Ettinger**

20:00-20:45 Opening Ceremony

Chair: **Alex Adjei, Kostas Syrigos**

20:00-20:15 Awards 2016
Paris Kosmidis
Rolf Stahel
Paul Bunn

20:15-20:45 Keynote lecture

The lung cancer therapeutic journey: 1974-2015. **Paul Bunn**

20:45 Welcome cocktail

SATURDAY January 16th 2016

09:00-10:30 Oncogene driver NSCLC

Chair: **Paul Bunn, Paris Kosmidis**

09:00-09:30 EGFR TKIs state of art 2016.

09:30-10:00 EML4-ALK TKIs state of art 2016.

10:00-10:30 Other targetable oncogenes in lung cancer.

**David Ettinger
Chandra Belani**

Alex Adjei

10:30-11:10 Evaluation of response

Chair: **Enriqueta Felip, Kostas Syrigos**

10:30-10:50 RECIST criteria in the post-chemotherapy era.

10:50-11:10 Next generation sequencing (NGS) testing:
when and for whom.

Paul Bunn

Gregory Riely

11:10-11:30 Coffee break

11:30-12:00 Invited Lecture

Chair: **Johan Vansteenkiste, Ioannis Boukovinas**

Masterprotocols in lung cancer.

Fred Hirsch

SATURDAY

January 16th

2016

12:00-13:30 Optimal use of the driver oncogenes TKIs

Chair: **Alex Adjei, Sofia Agelaki**

12:00-12:20 Early stages NSCLC.

Solange Peters

12:20-12:40 Integration of radiotherapy with TKIs treatment.

Lucio Crinó

12:40-13:00 Management of TKI toxicities.

Gregory Riely

13:00-13:20 Resistance to TKIs: molecular or clinical documentation?

David Carbone

13:20-13:30 Discussion

13:30-16:00 Lunch break

16:00-17:00 Molecular signature of lung cancer

Chair: **Solange Peters, Vassilis Gorgoulis**

16:00-16:15 The RAS/RAF pathway.

Alex Adjei

16:15-16:30 The HER2.

Enriqueta Felip

16:30-16:45 T790M inhibition.

Rolf Stahel

16:45-17:00 Discussion

17:00-18:00 Industry satellite symposium Sponsored by  Bristol-Myers Squibb

Chair: **Kostas Syrigos**

Immuno oncology in lung cancer: changing the treatment paradigm.

Solange Peters

18:00-18:30 Coffee break

18:30-20:30 Immunotherapy

Chair: **Lucio Crinó, Rolf Stahel**

18:30-18:50 Immune activation and checkpoint inhibition.

Vali Papadimitrakopoulou

18:50-19:10 Immune biomarkers and immune signature.

Thorsten Füreder

19:10-19:30 Which target? Which molecule?

Chandra Belani

19:30-19:50 Management of toxicities.

Solange Peters

19:50-20:10 Integration of immunotherapy to current treatment options.

Johan Vansteenkiste

20:10-20:30 Future strategies of lung cancer immunotherapy.

Rolf Stahel

20:30 Closing ceremony

Faculty

- Adjei Alex** MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia, Chair in Cancer Medicine Senior, Vice President for Clinical Research, Roswell Park Cancer Institute, USA
- Agelaki Sofia** Assistant Professor of Medical Oncology, University of Crete, Greece
- Belani Chandra** MD, Miriam Beckner Distinguished Professor of Medicine, Penn State College of Medicine, Head, Lung Cancer Program, Penn State Hershey Cancer Institute, USA
- Booton Richard** Dr, Consultant Respiratory Physician, Honorary Senior Lecturer in Respiratory Medicine Manchester Thoracic Oncology Centre, University Hospital of South Manchester, UK
- Boukovinas Ioannis** MD, PhD, Medical Oncologist, Head of Oncology Unit Bioclinic, Thessaloniki, Greece
- Brambilla Elisabeth** Professor of Pathology, Grenoble University Hospital, University Joseph Fourrier, Grenoble, France
- Bunn Paul Jr** MD, Distinguished Professor and James Dudley Endowed Chair in Lung Cancer Research, University of Colorado Cancer Centre, Aurora, CO, USA
- Carbone David** MD, PhD, Professor of Medicine, Director, James Thoracic Oncology Center, Barbara J. Bonner Chair in Lung Cancer Research, President, International Association for the Study of Lung Cancer (IASLC)
- Crinò Lucio** Professor, Director, Department of Medical Oncology, University Hospital, Perugia, Italy
- Dağlı Elif** Lecturer at Marmara University, Turkey
- Darlison Liz** Director of Services and Consultant Nurse, Mesothelioma UK, University Hospitals of Leicester NHS Trust, The Glenfield Hospital, Leicester, UK
- Den Bakker Michael** MD, PhD, Department of Pathology, Maastricht Hospital and Erasmus MC, Rotterdam, The Netherlands
- Ettinger David** MD, Alex Grass Professor of Oncology, Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- Felip Enriqueta** MD, PhD, Head, Thoracic Cancer Group, Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain, Associate Professor, Autonomous University of Barcelona (UAB)
- Füreder Thorsten** Assistant Professor, Dr, Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria
- Gkiozos Giannis** MD, PhD, FCCP, Pulmonologist, Clinical Fellow of Oncology Unite G'PP, Medical School of Athens, "Sotiria" Athens' Chest Diseases Hospital, Greece
- Gorgoulis Vassilis** Dr, MD, PhD, Professor-Director, Department of Histology-Embryology, Medical School, National Kapodistrian University of Athens, Greece
- Hirsch Fred** MD, PhD, Professor of Medicine and Pathology, Associate Director of International Programs, University of Colorado Cancer Center, USA, CEO of IASLC
- Kerr Keith** Professor, Consultant Pathologist, Department of Pathology, Aberdeen Royal Infirmary, Professor of Pulmonary Pathology, Aberdeen University Medical School, Foresterhill, Aberdeen, Scotland, UK

- Kittas Christos** Emeritus Professor of Histology and Embryology, School of Medicine, National and Kapodistrian University of Athens, Greece
- Kosmidis Paris** MD, Medical Oncologist, Head of 2nd Medical Oncology Department, “Hygeia” Hospital, Athens, Greece
- Mornex Françoise** MD, PhD, Radiation Oncologist, Centre Hospitalier Lyon Sud, Professor of Oncology at University Claude Bernard Lyon, France, Head of the Radiation Oncology Department, CHU de Lyon, France
- Papadimitrakopoulou Vali** MD, Jay and Lori Eisenberg Distinguished Professor, Professor of Medicine, Department of Thoracic/HN Medical Oncology, MD Anderson Cancer Center, Houston, USA
- Patsouris Efstratios** Professor, Dr, Chairman of 1st Department of Pathology, Medical School, University of Athens, Greece, Dean of School of Health Sciences
- Peled Nir** Professor, MD, PhD, FCCP, Pulmonologist and Medical Oncologist, Thoracic Cancer Unit, Davidoff Cancer Center, Israel, International Lung Cancer Association, Committee Chair, Prevention, Screening & Early Detection of Lung Cancer, IASLC
- Peters Solange** Dr, MD, PhD, Associate Professor, Chair Thoracic Malignances, Department of Oncology, University of Lausanne, Switzerland, Scientific Coordinator, European Thoracic Oncology Platform (ETOP)
- Rami-Porta Ramón** MD, Attending Thoracic Surgeon, Department of Thoracic Surgery, Hospital Universitari Mutua Terrassa, University of Barcelona, Terrassa, Barcelona, Spain
- Riely Gregory** Associate Member, Memorial Sloan Kettering Cancer Centre, Associate Attending Physician, Memorial Hospital, Vice Chair, Department of Medicine, Associate Professor, Weill Cornell Medical College, USA
- Stahel Rolf** MD, Head of the Center for Lung and Thoracic Oncology, Senior Staff Physician, Clinic of Oncology, University Hospital of Zurich, Titular Professor of Medicine, University of Zurich, Switzerland
- Swanton Charles** MB, PhD, FRCP, FMedSci, Professor of Cancer Medicine, Chair in Personalised Medicine, Director of Lung Cancer Centre of Excellence, Senior Group Leader, Consultant Medical Oncologist, UK
- Syrigos Kostas** MD, PhD, Professor of Medicine and Medical Oncology, Head, 3rd Department of Medicine, “Sotiria” General Hospital, Athens School of Medicine, National and Kapodistrian University of Athens, Greece, Vis. Professor of Thoracic Oncology, Yale School of Medicine, USA
- Travis William** MD, Attending Thoracic Pathologist, Memorial Sloan Kettering Cancer Center, Professor of Pathology, Weill Medical College of Cornell University, New York, USA
- Vansteenkiste Johan** MD, PhD, Professor of Medicine, Catholic University Leuven, Head of Clinic, Respiratory Oncology Unit and Trial Unit, Department of Pneumology, University Hospital Gasthuisberg, Belgium
- Yumuk Fulden** MD, Marmara University, Medical School, Turkey
- Zarogoulidis Kostas** Professor in Pulmonology-Tuberculosis, Director of Pulmonary-Tuberculosis Clinic, Aristotle University of Thessaloniki “G. Papanikolaou” General Hospital, Greece

Scientific Information

Meeting room - audiovisual - technical support

The meeting will take place at the “Hesperides” Hall and the meeting secretariat will operate at the “Hesperides” foyer during the sessions. The meeting room will be equipped with data video projectors, laser pointers etc for power point presentations. Technical support center will be available outside the “Hesperides” Hall. Technical staff will assist with the presentations. All speakers are kindly requested to submit their presentation at least one hour prior to their scheduled presentation.



Language

The official language of the congress is English.

CME Accreditation - Auspice

The content of the meeting will be submitted for CME accreditation. Accreditation will be received from the Panhellenic Medical Association. The meeting has requested the auspice of ESMO, IASLC and ETOP.

Name badges

All registered participants will receive name badges, which they are kindly requested to wear at all times. Each badge will have a barcode for monitoring the hours of attendance.

Certificate of Attendance

All registered participants who have attended at least 60% of the total scientific program will receive a certificate of attendance from the secretariat desk after the closing ceremony.

General information

Organized by the

Oncology Center of Biomedical Education and Research
Oncology Unit, 3rd Department of Medicine, Medical School of Athens

Meeting website

www.lungcancernetwork.eu

Meeting dates

January 15th & 16th, 2016

Meeting venue



Hilton Athens Hotel
46 Vassilissis Sofias Avenue
115 28 Athens, Greece
Tel.: 00 30 210 72 81 000

Conveniently situated in the heart of the city's commercial district, and just 25 minutes from the airport using the Athens Metro, the Hilton Athens' prime location and fabulous facilities make it the perfect spot for Athens meetings and exhibitions of all sizes.

Registration cost

Type of registration	Cost
Doctors*	200€
Residents	100€
Nurses	free
Medical students	free

Registration cost includes:

- Admission to all sessions & exhibition area
- Meeting material
- Certificate of attendance

* ESMO & IASLC Members will receive a 20% discount

Meeting's Secretariat



E.T.S. Events & Travel Solutions S.A.

El. Venizelou 154, 171 22 N. Smyrni - Athens, Greece

Tel.: +30 210 98 80 032, Fax: +30 210 98 81 303

E-mail: ets@otenet.gr, ets@events.gr, Website: www.events.gr